Sort

Search

01/12/2021 Predictive value of transcriptional expression of Kruppel-like factor-6 (KLF6) in head and neck carcinoma patients treated with radiotherapy
Leon, X, Venegas, M, Pujol, A, Bulboa, C, Llansana, A, Casasayas, M, Quer, M, Camacho, M. Predictive value of transcriptional expression of Kruppel-like factor-6 (KLF6) in head and neck carcinoma patients treated with radiotherapy. Clinical & Translational Oncology. 2021; 23(12)DOI:10.1007/s12094-021-02651-4. PMID:34061320. IF:3.340(Q3/7D).
01/12/2021 Timing of elective tracheotomy and duration of mechanical ventilation among patients admitted to intensive care with severe COVID-19: A multicenter prospective cohort study
Prats-Uribe, A, Tobed, M, Villacampa, JM, Aguero, A, Garcia-Bastida, C, Tato, JI, Rodriganez, L, Holguera, VD, Hernandez-Garcia, E, Poletti, D, Simonetti, G, Villarraga, V, Meler-Claramonte, C, Barrueco, AS, Chiesa-Estomba, C, Casasayas, M, Parente-Arias, P, Mata-Castro, N, Rello, J, Castro, P, Prieto-Alhambra, D, Vilaseca, I, Aviles-Jurado, FX. Timing of elective tracheotomy and duration of mechanical ventilation among patients admitted to intensive care with severe COVID-19: A multicenter prospective cohort study. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. 2021; 43(12)DOI:10.1002/hed.26863. PMID:34524714. IF:3.821(Q1/2D).
01/12/2021 An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
Jimenez, AMJ, De Lima, M, Komanduri, KV, Wang, TP, Zhang, MJ, Chen, KR, Abdel-Azim, H, Abid, MB, Aljurf, M, Alkhateeb, H, Assal, A, Bacher, U, Baron, F, Battiwalla, M, Beitinjaneh, A, Bejanyan, N, Bhatt, VR, Byrne, M, Cahn, JY, Cairo, M, Castillo, P, Copelan, E, DeFilipp, Z, Perez, MAD, Elsawy, M, Gale, RP, George, B, Grunwald, MR, Hildebrandt, GC, Hogan, WJ, Kanakry, CG, Kansagra, A, Kharfan-Dabaja, MA, Khera, N, Krem, MM, Lazaryan, A, Maakaron, J, Martino, R, McGuirk, J, Michelis, FV, Milone, G, Mishra, A, Murthy, HS, Mussetti, A, Nathan, S, Nishihori, T, Olsson, RF, Palmisiano, N, Patel, S, Saad, A, Seo, S, Sharma, A, Solh, M, Verdonck, LF, Wirk, B, Yared, JA, Litzow, M, Kebriaei, P, Hourigan, CS, Saber, W, Weisdorf, D. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. BONE MARROW TRANSPLANTATION. 2021; 56(12)DOI:10.1038/s41409-021-01450-3. PMID:34584240. IF:5.174(Q2/3D).
01/12/2021 Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma
Granell, M, Senin, A, Barata, A, Cibeira, MT, Gironella, M, Lopez-Pardo, J, Motllo, C, Garcia-Guinon, A, Ben-Azaiz, R, Abella, E, Soler, A, Canet, M, Marti, JM, Martino, R, Sierra, J, de Larrea, CF, Oriol, A, Rosinol, L. Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma. BONE MARROW TRANSPLANTATION. 2021; 56(12)DOI:10.1038/s41409-021-01429-0. PMID:34404917. IF:5.174(Q2/3D).
01/12/2021 Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
Diefenbach, C, Kahl, BS, McMillan, A, Briones, J, Banerjee, L, Cordoba, R, Miall, F, Burke, JM, Hirata, J, Jiang, YW, Paulson, JN, Chang, YM, Musick, L, Abrisqueta, P. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematology. 2021; 8(12)DOI:10.1016/S2352-3026(21)00311-2. PMID:34826412. IF:30.153(Q1/1D).
01/12/2021 Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
Wierda, WG, Allan, JN, Siddiqi, T, Kipps, TJ, Opat, S, Tedeschi, A, Badoux, XC, Kuss, BJ, Jackson, S, Moreno, C, Jacobs, R, Pagel, JM, Flinn, I, Pak, Y, Zhou, C, Szafer-Glusman, E, Ninomoto, J, Dean, JP, James, DF, Ghia, P, Tam, CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(34)DOI:10.1200/JCO.21.00807. PMID:34618601. IF:50.739(Q1/1D).